Clinical Trial Update: A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update covers a Phase 1b/2 study evaluating DeltEx, an activated, gene-modified γδ T cell therapy, in combination with maintenance temozolom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• DeltEx
• Temozolomide (Temozolomide)

Snippet

Sponsor: In8bio Inc. | Conditions: Glioblastoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING